TCERG1L

Summary

TCERG1L (transcription elongation regulator 1 like, HGNC:23533) is a protein-coding gene on chromosome 10q26.3, encoding Transcription elongation regulator 1-like protein (Q5VWI1).

Predicted to enable RNA polymerase binding activity and transcription coregulator activity. Predicted to be active in nucleus.

Source: NCBI Gene 256536 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 116 total — 1 pathogenic
• MANE Select transcript: NM_174937

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23533
Approved symbol	TCERG1L
Name	transcription elongation regulator 1 like
Location	10q26.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ38950
Ensembl gene	ENSG00000176769
Ensembl biotype	protein_coding
OMIM	620498
Entrez	256536

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 retained_intron

ENST00000368642, ENST00000483040, ENST00000935680

RefSeq mRNA: 1 — MANE Select: NM_174937 NM_174937

CCDS: CCDS7662

Canonical transcript exons

ENST00000368642 — 12 exons

Exon	Start	End
ENSE00001295373	131308211	131308391
ENSE00001315997	131260259	131260444
ENSE00001328907	131309153	131309299
ENSE00001852482	131311294	131311721
ENSE00003542433	131146506	131146660
ENSE00003554952	131116799	131116934
ENSE00003569340	131098306	131098424
ENSE00003600673	131166797	131166885
ENSE00003600836	131134379	131134448
ENSE00003635298	131163122	131163210
ENSE00003663450	131092391	131093318
ENSE00003680050	131104265	131104354

Expression profiles

Bgee: expression breadth ubiquitous, 103 present calls, max score 82.39.

FANTOM5 (CAGE): breadth broad, TPM avg 1.4448 / max 135.4559, expressed in 230 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
112053	1.1323	210
112051	0.1222	57
112054	0.0947	55
112052	0.0855	47
112049	0.0102	3

Top tissues by expression

231 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of thyroid gland	UBERON:0001119	82.39	gold quality
Brodmann (1909) area 23	UBERON:0013554	79.36	gold quality
left lobe of thyroid gland	UBERON:0001120	78.62	gold quality
middle temporal gyrus	UBERON:0002771	78.33	gold quality
thyroid gland	UBERON:0002046	78.25	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	75.77	gold quality
prefrontal cortex	UBERON:0000451	75.73	gold quality
Brodmann (1909) area 9	UBERON:0013540	75.61	gold quality
right frontal lobe	UBERON:0002810	75.00	gold quality
anterior cingulate cortex	UBERON:0009835	74.11	gold quality
frontal cortex	UBERON:0001870	73.96	gold quality
primary visual cortex	UBERON:0002436	73.89	gold quality
neocortex	UBERON:0001950	73.39	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	72.81	gold quality
pancreatic ductal cell	CL:0002079	72.75	silver quality
cerebral cortex	UBERON:0000956	71.38	gold quality
cortical plate	UBERON:0005343	71.04	gold quality
islet of Langerhans	UBERON:0000006	70.56	gold quality
superior frontal gyrus	UBERON:0002661	69.35	gold quality
tibialis anterior	UBERON:0001385	67.33	silver quality
occipital lobe	UBERON:0002021	66.87	gold quality
left ovary	UBERON:0002119	66.11	gold quality
corpus epididymis	UBERON:0004359	65.42	gold quality
cauda epididymis	UBERON:0004360	65.10	gold quality
right hemisphere of cerebellum	UBERON:0014890	63.76	gold quality
hypothalamus	UBERON:0001898	63.70	gold quality
ovary	UBERON:0000992	63.32	gold quality
cerebellar cortex	UBERON:0002129	63.11	gold quality
cerebellar hemisphere	UBERON:0002245	63.06	gold quality
cerebellum	UBERON:0002037	62.70	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.57

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

39 targeting TCERG1L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-493-5P	99.96	72.47	2382
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-7845-5P	99.88	64.88	771
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-448	99.79	72.37	2103
HSA-MIR-4517	99.76	69.19	1867
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-372-5P	99.41	69.11	2299
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-1272	99.34	68.79	878
HSA-MIR-16-2-3P	99.29	70.60	1954
HSA-MIR-195-3P	99.29	70.61	1954
HSA-MIR-4254	99.11	65.15	1315

Literature-anchored findings (GeneRIF, showing 1)

• TCERG1L is associated with plasma adiponectin, a key modulator of obesity, inflammation, IR and diabetes. (PMID:22791750)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tcerg1l	ENSDARG00000109963
mus_musculus	Tcerg1l	ENSMUSG00000091002
rattus_norvegicus	Tcerg1l	ENSRNOG00000016737

Paralogs (2): ARHGAP5 (ENSG00000100852), TCERG1 (ENSG00000113649)

Protein

Protein identifiers

Transcription elongation regulator 1-like protein — Q5VWI1 (reviewed: Q5VWI1)

All UniProt accessions (1): Q5VWI1

RefSeq proteins (1): NP_777597* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001202	WW_dom	Domain
IPR002713	FF_domain	Domain
IPR036020	WW_dom_sf	Homologous_superfamily
IPR036517	FF_domain_sf	Homologous_superfamily
IPR045148	TCRG1-like	Family
IPR057565	WW_TCRG1_3rd	Domain

Pfam: PF01846, PF23517

UniProt features (18 total): compositionally biased region 5, domain 4, sequence variant 4, region of interest 3, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5VWI1-F1	59.13	0.23

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 63 (showing top): ACTGCAG_MIR173P, TCF4_Q5, FREAC3_01, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, AACTTT_UNKNOWN, TGAGATT_MIR216, CTTTGTA_MIR524, TTTNNANAGCYR_UNKNOWN, AGCYRWTTC_UNKNOWN, YATGNWAAT_OCT_C, GOMF_RNA_POLYMERASE_BINDING, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3, MEISSNER_NPC_HCP_WITH_H3K4ME2, MIKKELSEN_MCV6_HCP_WITH_H3K27ME3, YRCCAKNNGNCGC_UNKNOWN

GO Biological Process (0):

GO Molecular Function (3): transcription coregulator activity (GO:0003712), RNA polymerase binding (GO:0070063), protein binding (GO:0005515)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription regulator activity	1
enzyme binding	1
binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1110 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TCERG1L	TAFA5	Q7Z5A7	574
TCERG1L	SCCPDH	Q8NBX0	524
TCERG1L	TMEM132D	Q14C87	484
TCERG1L	PLXND1	Q9Y4D7	456
TCERG1L	LDB2	O43679	444
TCERG1L	CHST8	Q9H2A9	437
TCERG1L	DPYSL4	O14531	426
TCERG1L	ARHGEF10	O15013	425
TCERG1L	GSTO2	Q9H4Y5	418
TCERG1L	PROSER2	Q86WR7	413
TCERG1L	OPCML	Q14982	412
TCERG1L	POLR1D	P0DPB6	407
TCERG1L	SGSM1	Q2NKQ1	405
TCERG1L	ZFPM2	Q8WW38	405
TCERG1L	SYNJ2	O15056	398

IntAct

0 interactions, top by confidence:

BioGRID (3): TCERG1L (Co-fractionation), TCERG1L (Cross-Linking-MS (XL-MS)), TCERG1L (Affinity Capture-RNA)

ESM2 similar proteins: A5X7A0, A7XW16, F1N8V3, G5E5X0, O15055, O94993, P48031, P52951, P56645, Q00175, Q04891, Q08050, Q29RJ0, Q2MJB4, Q3B807, Q3UH66, Q3UWW6, Q5VWI1, Q5XHX9, Q63449, Q69ZH9, Q6A0A2, Q6U8D7, Q76I79, Q76IQ7, Q7T1K4, Q7Z3H4, Q80VX4, Q86V15, Q8C0C0, Q8C0Y1, Q8CH09, Q8IX01, Q8JIT7, Q8K3T2, Q8VIG0, Q8WNV5, Q8WYL5, Q91Z96, Q92615

Diamond homologs: B6EUA9, F4JCC1, O14776, O75400, Q3B807, Q5VWI1, Q6NWY9, Q80W14, Q8CGF7, Q9R1C7, P34600, O04425

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

116 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	97
Likely benign	10
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2671973	GRCh37/hg19 10q26.2-26.3(chr10:128289206-135427143)x1	Pathogenic

SpliceAI

3669 predictions. Top by Δscore:

Variant	Effect	Δscore
10:131098422:TAT:T	acceptor_gain	1.0000
10:131098425:C:CC	acceptor_gain	1.0000
10:131098426:T:C	acceptor_gain	1.0000
10:131098426:T:TC	acceptor_gain	1.0000
10:131116797:AC:A	donor_gain	1.0000
10:131116797:ACC:A	donor_gain	1.0000
10:131116798:CC:C	donor_gain	1.0000
10:131116798:CCC:C	donor_gain	1.0000
10:131116798:CCCCT:C	donor_gain	1.0000
10:131134377:A:AC	donor_gain	1.0000
10:131134378:C:CC	donor_gain	1.0000
10:131134445:TCAG:T	acceptor_gain	1.0000
10:131134446:CAG:C	acceptor_gain	1.0000
10:131134446:CAGC:C	acceptor_gain	1.0000
10:131134447:AG:A	acceptor_gain	1.0000
10:131134447:AGCTG:A	acceptor_loss	1.0000
10:131134449:C:CC	acceptor_gain	1.0000
10:131134449:CTG:C	acceptor_loss	1.0000
10:131134450:T:A	acceptor_loss	1.0000
10:131146504:A:AC	donor_gain	1.0000
10:131146505:C:CC	donor_gain	1.0000
10:131146505:CTTG:C	donor_gain	1.0000
10:131146656:CACAC:C	acceptor_gain	1.0000
10:131146659:ACC:A	acceptor_loss	1.0000
10:131146660:CCTG:C	acceptor_loss	1.0000
10:131146662:T:A	acceptor_loss	1.0000
10:131165904:CA:C	acceptor_gain	1.0000
10:131165905:A:C	acceptor_gain	1.0000
10:131166792:CTGA:C	donor_loss	1.0000
10:131166794:GAC:G	donor_loss	1.0000

AlphaMissense

3796 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:131146594:C:A	W367C	1.000
10:131146594:C:G	W367C	1.000
10:131093301:A:G	F541S	0.999
10:131098333:A:G	L526P	0.999
10:131104307:A:C	F481L	0.999
10:131104307:A:T	F481L	0.999
10:131104309:A:G	F481L	0.999
10:131104334:C:A	W472C	0.999
10:131104334:C:G	W472C	0.999
10:131146596:A:G	W367R	0.999
10:131146596:A:T	W367R	0.999
10:131146627:G:C	F356L	0.999
10:131146627:G:T	F356L	0.999
10:131146629:A:G	F356L	0.999
10:131146648:C:A	W349C	0.999
10:131146648:C:G	W349C	0.999
10:131146650:A:G	W349R	0.999
10:131146650:A:T	W349R	0.999
10:131163123:A:G	W345R	0.999
10:131163123:A:T	W345R	0.999
10:131093300:A:C	F541L	0.998
10:131093300:A:T	F541L	0.998
10:131093302:A:G	F541L	0.998
10:131098330:A:G	L527P	0.998
10:131098342:A:G	F523S	0.998
10:131098419:A:C	F497L	0.998
10:131098419:A:T	F497L	0.998
10:131098421:A:G	F497L	0.998
10:131104272:C:G	R493P	0.998
10:131104336:A:G	W472R	0.998

dbSNP variants (sampled 300 via entrez): RS1000001405 (10:131194871 G>C), RS1000043340 (10:131155454 C>G,T), RS1000044777 (10:131175878 G>T), RS1000047657 (10:131169713 T>G), RS1000059359 (10:131183752 G>A), RS1000071166 (10:131291945 A>C), RS1000083351 (10:131108237 G>A), RS1000083686 (10:131224837 T>A), RS1000097618 (10:131143227 C>T), RS1000102367 (10:131274980 C>A,T), RS1000115776 (10:131183355 T>C), RS1000116654 (10:131242057 G>A), RS1000120307 (10:131257065 A>C), RS1000126015 (10:131145566 G>T), RS1000129486 (10:131157726 C>A,T)

Disease associations

OMIM: gene MIM:620498 | disease phenotypes: MIM:609625

GenCC curated gene-disease

Mondo (2): primary ovarian failure (MONDO:0005387), distal 10q deletion syndrome (MONDO:0012315)

Orphanet (2): Distal deletion 10q syndrome (Orphanet:96148), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST001033_14	Type 2 diabetes	5.000000e-06
GCST001438_8	Crohn’s disease	3.000000e-08
GCST001531_1	Temperament	7.000000e-06
GCST001604_4	Insulin-related traits	3.000000e-08
GCST004749_29	Lung cancer in ever smokers	1.000000e-06
GCST005790_20	Rosacea symptom severity	9.000000e-06
GCST007626_1	Lack of perseverance	1.000000e-07
GCST008163_430	Height	3.000000e-06
GCST009172_3	Response to (pegylated) interferon in HBeAg-negative hepatitis B	3.000000e-06
GCST010151_19	Carotid intima media thickness x smoking interaction	6.000000e-06
GCST90013831_1	Cisplatin-induced hearing loss in childhood cancer	5.000000e-10

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004825	temperament and character inventory
EFO:0009180	rosacea severity measurement
EFO:0006946	behavioural disinhibition measurement
EFO:0007859	response to interferon
EFO:0006527	smoking status measurement
EFO:0006951	ototoxicity

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750
C567182	Chromosome 10q26 Deletion Syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, increases methylation, affects cotreatment	8
trichostatin A	affects cotreatment, increases expression, decreases expression	4
Resveratrol	affects cotreatment, decreases expression	2
Benzo(a)pyrene	affects methylation, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
bisphenol A	decreases methylation	1
terbufos	increases methylation	1
arsenite	increases methylation	1
benzo(e)pyrene	increases methylation	1
ferrous chloride	increases expression	1
aflatoxin B2	increases methylation	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
2,2’,4,4’,5-brominated diphenyl ether	increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
Decitabine	affects expression	1
Vorinostat	affects cotreatment, increases expression	1
Cisplatin	affects expression	1
Copper	affects cotreatment, decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Fonofos	increases methylation	1
Folic Acid	decreases expression	1
Formaldehyde	decreases expression	1
Methapyrilene	increases methylation	1
Parathion	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Tretinoin	increases expression	1
Aflatoxin B1	decreases methylation	1

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists